According to a study funded by Amgen Inc., the incidence of stage IV prostate cancer has significantly declined and survival has improved, but the scary side of the equation is that younger men represent an increasing proportion of those diagnosed. The study was published in the June issue of Urology. […]
According to the FDA approval label, zoledronic acid (Zometa) should be administered to men with advanced prostate cancer once they have failed one hormone therapy type, in other words, once the cancer has become castrate resistant. Researchers at the Centre Hospitalier de i’Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada evaluated the effect of zoledronic [...]
Results from a recent clinical trial indicate that denosumab delayed the spread of prostate cancer metastases bones, however it did not prolong the lives of men. […]
Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]
In order to get FDA approval, drugs must first go through a clinical trial that demonstrates that they offer a better treatment result than the current standard of care. In some instances the better result can be a demonstration that the investigational drug provides an advantage which is only palliative (as Mitoxantrone does for advance [...]